Slide 1: HY 2018 Results Conference Call
me cegedim Hi 2018 Results Conference Call September 17", 2018
Slide 2: Caution Concerning Forward-Looking Statements
Caution Concerning Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but that
Slide 3: Agenda
Agenda Cegedim Strategy Finance Appendices at glance
Slide 4: Cegedim at glance
Cegedim at glance IGAlTACAarE pete now SOCAN
Slide 5: Cegedim at Glance FY 2017
Cegedim at Glance FY 2017 5 © cegedim 2018
Slide 6: Cegedim Key Figures
Cegedim Key Figures 6 © cegedim 2018
Slide 7: Shareholder Structure as of June 30, 2018
Shareholder Structure as of June 30, 2018 7 © cegedim 2018
Slide 8: Cegedim: Unique Connected Healthcare Ecosystem
Cegedim: Unique Connected Healthcare 8 Ecosystem © cegedim 2018
Slide 9: Cegedim: Key Facts
Cegedim: Key Facts 9 © cegedim 2018
Slide 10: Strong Position
Strong Position 10 © cegedim 2018
Slide 11: Our Clients, Our Divisions
Our Clients, Our Divisions 11 © cegedim 2018
Slide 12: Health Insurance, HR and e-services Division
Health Insurance, HR and e-services Division 12 © cegedim 2018
Slide 13: Overview: Health Insurance, HR & e-services solutions
Overview: Health Insurance, HR & e-services solutions 13 © cegedim 2018
Slide 14: Healthcare Professionals Division
Healthcare Professionals Division 14 © cegedim 2018
Slide 15: Overview: Healthcare Professionals Solutions
Overview: Healthcare Professionals Solutions 15 © cegedim 2018
Slide 16: Strategy
Strategy
Slide 17: Global trends
Global trends 17 © cegedim 2018
Slide 18: Chronology
Chronology HY 2018 Results 2018 Fine-tuning the 2020 / updated Business Model Business Model 1999 Transformation 2015 & @ 7 Pd eee = Development 1999 P 1969 - 4 1979 -s ® = _—p International Expansion 5S 1995: IPO of Cegedim Origin on Euronext Paris © cegedim 2018
Slide 19: Cegedim has achieved a successful transforming plan
Cegedim has achieved a successfull transforming plan 19 19 © cegedim 2018
Slide 20: A Renewed Business Model
A Renewed Business Model 20 © cegedim 2018
Slide 21: Small bolt on acquisition
Small bolt on acquisition 21 21 © cegedim 2018
Slide 22: Strong R&D capacities supporting innovation efforts
Strong R&D capacities supporting innovation efforts 22 22 © cegedim 2018
Slide 23: Docavenue: Moving to telemedicine
Docavenue: Moving to telemedicine 23 © cegedim 2018
Slide 24: Finance
Finance IFRS 5 Cegedim announced on December 14, 2017 that it had signed a contract for the definitive sale of its Cegelease and Eurofarmat businesses. As a result, the consolidated 2017 and 2018 financial statements are presented according to IFRS 5, “Non-current assets held for sale and discontinu
Slide 25: IFRS Rules
IFRS Rules 25 IFRS 5 : Owing to the disposal of the Group’s Cegelease and Eurofarmat businesses, announced in 2017 and completed on February 28, 2018, the consolidated 2017 and 2018 financial statements are presented according to IFRS 5, “Non-current assets held for sale and discontinued”. See the a
Slide 26: 2018 First-Half Results
2018 First-Half Results HY 2018 Results GROUP REVENUE GROUP EBITDA GROUP EBITDA MARGIN + €3.6m 6m 633.3m 14.6% €224.1m ©2276 on = S 18.3% fi ail WW Wt ta Hs j WW) WIS i ECE FROM OPERATIONS NET DEBT €11.4m +6.3m m _ + €76.5)m i i Wf , ee 2.2017 shuctural improvement = Increase in FCF generation | Net
Slide 27: HY 2018 Profit & Loss Statement
HY 2018 Profit & Loss Statement 27 In € million HY 17 HY 18 % change Revenue 224.1 227.6 +1.6% EBITDA 29.8 33.3 +11.8% Margin 13.3% 14.6% +134bps D&A (19.5) (21.4) +9.3% EBIT before special items 10.2 11.9 +16.7% Margin 4.6% 5.2% +68bps Special items (11.7) (9.6) (17.8)% EBIT (1.5) 2.3 n.m. Margin (
Slide 28: HY 2018 Revenue Growth
HY 2018 Revenue Growth 28 © cegedim 2018
Slide 29: BPO Revenue
BPO Revenue 29 7 © cegedim 2018
Slide 30: Headcount
Headcount HY 2018 Results ~ +1.8% ) x +4.8% )—» =e +18.6% = = Zo 4,230 4,307 Se DEC. 2016 Dec. 20 JUN. 2018 SSS eg = me me = a
Slide 31: Well diversified revenue source
Well diversified revenue source 31
Slide 32: HY 2018 EBITDA Trend
HY 2018 EBITDA Trend HY 2018 Results +l % +5$% —#37.4% €1.6m €33.3m {—— LO (81) (0) een €6.3m cm GE Eo : €(6.5)m HV REVENUE == PURCHASES EXTERNAL PAYROLL. «==OTHERS = AY WB USED = EYPENSES USED
Slide 33: Group EBITDA margin
Group EBITDA margin HY 2018 Results 20.4% 11.6% 14.6% 13.3% i W i W tL 1b lb I} V) I H1 18 EBITDA margin: up 134 bps to 14.6% compared with the same period in 2017. |
Slide 34: HY 2018: From EBITDA to Net Earnings
HY 2018: From EBITDA to Net Earnings 34
Slide 35: HY 2018 Profit & Loss Statement
HY 2018 Profit & Loss Statement 35 In € million HY 17 HY 18 % change Revenue 224.1 227.6 +1.6% EBITDA 29.8 33.3 +11.8% Margin 13.3% 14.6% +134bps D&A (19.5) (21.4) +9.3% EBIT before special items 10.2 11.9 +16.7% Margin 4.6% 5.2% +68bps Special items (11.7) (9.6) (17.8)% EBIT (1.5) 2.3 n.m. Margin (
Slide 36: Health Insurance, HR & e-services Division
Health Insurance, HR & e-services Division 36 The businesses that made the biggest contributions to first-half revenue growth were Cegedim SRH (HR management solutions), Cegedim e-business (digitalization and data exchange), sales statistics for pharmaceutical products, and third-party payment flow
Slide 37: Healthcare Professionals Division
Healthcare Professionals Division 37 As expected, first-half revenue were hampered by the doctor computerization businesses in the US, the UK and Spain ahead of the release of new versions, whose impact will not be felt until 2019. EBITDA fell mainly because of doctor computerization activities in t
Slide 38: Corporate & Other Division
Corporate & Other Division 38 EBITDA growth is attributable to the performance of Cegedim_IT
Slide 39: FCF from Operations
FCF from Operations 39 In € million HY 17 HY 18 Cash flow before taxes and interests 34.1 28.3 Change in working capital requirement 3.8 +11.5 Corporate tax paid (2.2) (0.7) Net cash flow from operating activities 35.6 39.1 Acquisition of intangible assets (23.9) (22.2) Acquisition of tangible asset
Slide 40: HY 2018 Net Debt Bridge
HY 2018 Results €236.2m => : = HY 2018 Net Debt Bridge €(I6 5% Ba €1.6m €1.6m €159.7m €(64.5)m €(3.8)m E | NET DEBT {CTRROM DISPOSAL’ INTERESTS TREASURERSHTP OTHER NET DEBT Dec V OPERATIONS — ACQUISITION PAID. = TMPACTFROM = MOVEMENTS = JUN.IS NET M&A
Slide 41: HY 2018 Balance Sheet
HY 2018 Balance Sheet 41 In € million Dec. 17 Jun.18 Assets Goodwill 167.8 173.3 Intangible assets 145.8 151.2 Tangible assets 33.2 33.4 Financial assets 20.4 19.5 Other non-current assets 38.1 40.0 Cash & Cash equivalent 18.7 13.6 Trade receivables, short term portion 118.2 110.0 Other current asse
Slide 42: HY 2018 Balance Sheet
HY 2018 Balance Sheet 42 42 © cegedim 2018
Slide 43: FY 2018 Cegedim Outlook
FY 2018 Cegedim Outlook Finance as of September 17, 2018
Slide 44: Outlook: Cautiously Optimistic for 2018
Outlook: Cautiously Optimistic for 2018 44 • Building on its successful actions in 2017, Cegedim continues to pursue a strategy of focusing on ORGANIC GROWTH fueled by a policy of SUSTAINED INNOVATION • The Group expects for 2018: 44 These projections are publicly disclosed on Sep. 17, 2018. The fac
Slide 45: Potential Impact of Brexit
Potential Impact of Brexit 45 • Cegedim operates in the UK in local currency, as it does in all the countries where it operates • No major European health program is at work in the UK 45 © cegedim 2018
Slide 46: 2018 Financial Calendar
2018 Financial Calendar 46 17 © cegedim 2018
Slide 47: Follow us
Follow us 47 WEB SITE www.cegedim.com/finance IR APP WEBCAST CEGEDIM IR SOCIAL NETWORK 18 @cegedimgroup © cegedim 2018
Slide 48: A strong leadership
A strong leadership 48 © cegedim 2018
Slide 49: Top market positions on a highly competitive international environment
Top market positions on a highly competitive 49 international environment © cegedim 2018
Slide 50: HY 2018 Earnings Appendices
HY 2018 Earnings Appendices
Slide 51: Application of IFRS 5
Application of IFRS 5 51 On December 14, 2017, Cegedim announced that it had signed a contract for the definitive sale of its Cegelease and Eurofarmat businesses. The deal was finalized on February 28, 2018. As a result, the consolidated 2017 and 2018 financial statements are presented according to
Slide 52: Jan Eryk Umiastowski
Jan Eryk Umiastowski Chief Investment Officer – Head of Investor Relations janeryk.umiastowski@cegedim.com Tel: 00 33 1 49 09 33 36 – Mob: 00 33 6 73 25 96 34 Design: Group Communications Department